Westlake Village BioPartners — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
BiotechMenlo Park, US
Rekha Hemrajani(Executive Officer)Merdad Parsey(Executive Officer, Director)
BoardDavid Mott(Director)James Young(Director)Robert Garland(Director)
Board seatBeth Seidenberg· per SEC Form D · $80M raise · filed Jan 2021
Co-investorsKleiner Perkins
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatDavid Allison· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicvenBio Partners
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)DAVID ALLISON(Director)KLAUS VEITINGER(Director)JAMES O'MARA(Executive Officer, Director)
Board seatDavid Allison· per SEC Form D · filed Jul 2021
Co-investors5AM VenturesOrbiMedSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global Strategic
BiotechSan Francisco, US
Kristine M Ball(Executive Officer, Director)Zachary Hill(Executive Officer, Director)
BoardNisha Marathe(Director)Keno Gutierrez(Director)David Morris(Director)
Board seatDavid Allison· per SEC Form D · $42.2M raise · filed May 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.